Cancer
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
Tackling cancer is a major global priority. Early detection and diagnosis can help patients get timely access to treatment and dramatically improve cancer outcomes. This relies, in part, on the effective diagnostic tests.
The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
24 January 2024
Cervical cancer imposes a substantial burden on patients, their support networks, the NHS, and society at large. This report underscores the significant socioeconomic savings that can be achieved by reaching the WHO’s elimination goal of 4 cases per 100,000 women, providing further impetus to take action to reach the ambitious 2040 elimination target set by NHS England.
Could Plant-based Diets Transform Health Care Spending?
8 January 2024
In a bid to reduce health care budgets, policymakers and healthcare professionals are increasingly looking to prevention strategies.
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
5 December 2023
Despite recommendations from medical societies, and support for its clinical and economic value, uptake of next-generation sequencing (NGS) has been slow in Europe, and access continues to be an issue.
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
Histology independent therapies are changing the picture of cancer treatment and in so doing don’t ‘fit the frame’ of value assessment. What are the key challenges…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…
What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment
2 January 2020
The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and…